OTC · Biotechnology

HBM Holdings Limited (HBMHF) Stock

$1.56 +0.00% OTC: HBMHF Healthcare

HBM Holdings Limited is a biopharmaceutical company in the clinical development phase, dedicated to the discovery and advancement of differentiated antibody therapeutics for immunological and oncological disorders. The firm's robust pipeline includes several notable candidates: Batoclimab (HBM9161), a human monoclonal antibody designed to selectively bind to and inhibit the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036), intended to address moderate to severe dry eye disease; HBM7008, a bispecific antibody engineered to engage tumor-associated antigens; and HBM4003, a human anti-CTLA-4 antibody directed against cytotoxic T-lymphocyte-associated antigen-4.

Valuation

MetricValue
Price$1.56
Market Cap$1.30B
P/E Ratio23.09
P/B Ratio3.66
P/S Ratio12.60
EPS (TTM)$0.07
52-Week High$2.54
52-Week Low$1.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE17.09%
ROA11.10%
ROCE11.23%
Gross Margin92.85%
Operating Margin43.28%
Net Margin51.67%
Debt/Equity0.22
Current Ratio5.17

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$41.0M$90.0M$38.0M$158.0M
Operating Profit$-143.0M$-122.0M$22.0M$-2.0M$81.0M
Net Profit$-137.0M$-138.0M$23.0M$3.0M$91.0M
EPS$-0.19$-0.19$0.03$0.00$0.11
Op Margin-3319.4%-299.8%24.4%-5.7%51.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$282.0M$232.0M$228.0M$215.0M$500.0M
Total Liabilities$59.0M$139.0M$109.0M$91.0M$133.0M
Cash$56.0M$162.0M$140.0M$167.0M$402.0M
Borrowings$19.0M$91.0M$66.0M$61.0M$82.0M

Latest News

Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases PR Newswire · Jul 23, 2026 Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma PR Newswire · Jul 15, 2026 Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases PR Newswire · Jul 2, 2026 Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology PR Newswire · Jun 29, 2026 Harbour BioMed and BioMap Jointly Initiate MegaStream TechBio: A Leading Global Drug Development Platform Joins Forces with Premier Life Science Foundation Models to Set New Benchmarks for AI-Driven Complex Biologics R&D PR Newswire · Jun 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-123.0M$-99.0M$-19.0M$31.0M$81.0M
Investing Cash Flow$-92.0M$122.0M$26.0M$6.0M$-191.0M
Financing Cash Flow$-10.0M$-5.0M$-4.0M$-5.0M$-29.0M
Net Cash Flow$-200.0M$106.0M$-21.0M$26.0M$60.0M
Free Cash Flow$-137.0M$-117.0M$-22.0M$30.0M$70.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA21.36
FCF Yield38.75%
Quick Ratio5.10
Interest Coverage28.35
Return 1Y41.82%
Return 3Y223.65%
Return 5Y—

Ownership

Insiders Held21.00%
Institutions Held23.29%
Institutions Float Held29.48%
Institutional HolderSharesReport Date
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund9,228,0002026-04-30
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund6,160,0002026-03-31
iShares Trust-iShares Core MSCI EAFE ETF4,362,0002026-06-30
DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT.2,658,0002026-04-30
iShares Trust-iShares MSCI EAFE Small-Cap ETF2,389,0002026-05-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $2.27 -0.66% -1.17 $163.60M 0.00%
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
ANEBAnebulo Pharmaceuticals, Inc. $0.34 +0.00% -1.73 $13.72M 0.00%
BPTHBio-Path Holdings, Inc. $0.04 +0.00% -0.05 $355002 0.00%
CING $4.52 -2.59% -1.08 $25.34M 0.00%

About HBM Holdings Limited

HBM Holdings Limited is a biopharmaceutical company in the clinical development phase, dedicated to the discovery and advancement of differentiated antibody therapeutics for immunological and oncological disorders. The firm's robust pipeline includes several notable candidates: Batoclimab (HBM9161), a human monoclonal antibody designed to selectively bind to and inhibit the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036), intended to address moderate to severe dry eye disease; HBM7008, a bispecific antibody engineered to engage tumor-associated antigens; and HBM4003, a human anti-CTLA-4 antibody directed against cytotoxic T-lymphocyte-associated antigen-4. Furthermore, HBM is advancing HBM9022 as a treatment for SARS-COV-2, HBM9302 for breast and gastric cancers, and HBM7020 for multiple myeloma. A diverse array of other compounds, such as HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022, are also under development for various solid tumors. HBM Holdings maintains a global operational footprint, spanning Mainland China, the United States, Europe, and other international territories. The company has established strategic partnerships for antibody-drug conjugate (ADC) initiatives with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. Incorporated in 2016, HBM Holdings Limited's corporate headquarters are located in Shanghai, People's Republic of China.

HBM Holdings Limited is headquartered in CN.

HBM Holdings Limited (HBMHF) stock trades at $1.56 with a market capitalization of $1.30B. The stock is valued at a price-to-earnings (P/E) ratio of 23.09, price-to-book of 3.66, price-to-sales of 12.60. Over the past 52 weeks the stock has ranged between $1.10 and $2.54, and currently trades 38.6% below its 52-week high.

On profitability, HBM Holdings Limited generates a return on equity (ROE) of 17.09%, above the typical market average, return on capital employed of 11.23%, an operating margin of 43.28%, a net profit margin of 51.67%.

Official website: www.harbourbiomed.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides